The study shows that the human peptide LL‑37 (and similar chicken peptides) can change chicken immune cells by making them better at grabbing and showing off foreign bits, while also calming down inflammation caused by bacterial toxins. However, this was done in chicken blood cells, not humans, so it doesn’t give clear guidance for personal health use.

Cathelicidins display in vitro and in vivo immunomodulatory activities and are part of the innate immune system. Previously, we found that in ovo treatment with chicken cathelicidin CATH-2 partially protects young broilers against respiratory E. coli infection. To determine the cellular aspects of this protection, we investigated immunomodulatory effects of CATH-2 and the human cathelicidin LL-37 on primary chicken peripheral blood mononuclear cells (PBMCs). Treatment of chicken PBMCs with L-CATH-2, D-CATH-2 or LL-37 increased the percentage of mononuclear phagocytes, but decreased that of B cells. L-CATH-2, D-CATH-2 and LL-37 treatment of chicken PBMCs also enhanced the expression levels of mannose receptor MRC1 and antigen presentation markers MHCII, CD40 and CD86 on mononuclear phagocytes, indicating increased antigen presentation capacity. Concomitantly, L-CATH-2, D-CATH-2 and LL-37 neutralized LPS-induced cytokine production, while increasing the endocytic capacity. We conclude that L-CATH-2, D-CATH-2 and LL-37 can modulate the immune response of primary chicken immune cells by increasing mannose receptor expression, antigen presentation, endocytosis and neutralizing LPS-induced cytokine production and as a result augment activation of the adaptive immune system.